... vedotin) — Used to treat some cases of non-Hodgkin lymphoma Zynlonta (loncastuximab tesirine) — Used to treat some people who have relapsed or refractory (treatment-resistant) large B-cell lymphoma Monoclonal antibodies include: Poteligeo (mogamulizumab-kpkc) — Used to treat two rare forms of non-Hodgkin lymphoma: Sezary syndrome and mycosis fungoides Monjuvi ...
... vedotin) — Used to treat some cases of non-Hodgkin lymphoma Zynlonta (loncastuximab tesirine) — Used to treat some people who have relapsed or refractory (treatment-resistant) large B-cell lymphoma Monoclonal antibodies include: Poteligeo (mogamulizumab-kpkc) — Used to treat two rare forms of non-Hodgkin lymphoma: Sezary syndrome and mycosis fungoides Monjuvi ...
... Another option for people whose FL has come back or hasn’t responded to other treatments is tafasitamab-cxix (Monjuvi), a monoclonal antibody used with lenalidomide and rituximab.Your cancer care team may also recommend a chemotherapy regimen along with prednisone to help lower the number of extra B cells. ...
... Another option for people whose FL has come back or hasn’t responded to other treatments is tafasitamab-cxix (Monjuvi), a monoclonal antibody used with lenalidomide and rituximab.Your cancer care team may also recommend a chemotherapy regimen along with prednisone to help lower the number of extra B cells. ...
... If you’re not eligible for a bone marrow transplant, your oncologist may recommend the following: Polatuzumab vedotin-piiq (Polivy) with or without bendamustine and/or rituximab Gemcitabine plus oxaliplatin (GemOx) with or without rituximab Tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) Third-Line Treatment OptionsIf your first two treatments ...
... If you’re not eligible for a bone marrow transplant, your oncologist may recommend the following: Polatuzumab vedotin-piiq (Polivy) with or without bendamustine and/or rituximab Gemcitabine plus oxaliplatin (GemOx) with or without rituximab Tafasitamab-cxix (Monjuvi) plus lenalidomide (Revlimid) Third-Line Treatment OptionsIf your first two treatments ...
... specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) – Approved in May 2024 Epcoritamab-bysp (Epinkly) — Approved in June 2024 Tafasitamab-cxix (Monjuvi ...
... specifically for treatment of relapsed or refractory follicular lymphoma: Tisagenlecleucel (Kymriah) — Approved in May 2022 Mosunetuzumab-axgb (Lunsumio) — Approved in December 2022 Zanubrutinib (Brukinsa) — Approved in March 2024 Lisocabtagene maraleucel (Breyanzi) – Approved in May 2024 Epcoritamab-bysp (Epinkly) — Approved in June 2024 Tafasitamab-cxix (Monjuvi ...
... Examples include drugs that target: CD20 — Obinutuzumab (Gazyva), ofatumumab, and rituximab Bispecific T-cell engagers — Epcoritamab-bysp (Epkinly), glofitamab-gxmb (Columvi), and mosunetuzumab-axgb (Lunsumio) CD19 on B lymphocytes — Tafasitamab-cxix (Monjuvi) Monoclonal antibodies that target antigens on cancer cells can also be combined with chemotherapy ...
... Examples include drugs that target: CD20 — Obinutuzumab (Gazyva), ofatumumab, and rituximab Bispecific T-cell engagers — Epcoritamab-bysp (Epkinly), glofitamab-gxmb (Columvi), and mosunetuzumab-axgb (Lunsumio) CD19 on B lymphocytes — Tafasitamab-cxix (Monjuvi) Monoclonal antibodies that target antigens on cancer cells can also be combined with chemotherapy ...
... Bispecific T-cell engagers approved to treat follicular lymphoma in some cases include: Epcoritamab-bysp (Epkinly) Mosunetuzumab-axgb (Lunsumio) Another type of immunotherapy is tafasitamab-cxix (Monjuvi), a monoclonal antibody approved in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.Targeted ...
... Bispecific T-cell engagers approved to treat follicular lymphoma in some cases include: Epcoritamab-bysp (Epkinly) Mosunetuzumab-axgb (Lunsumio) Another type of immunotherapy is tafasitamab-cxix (Monjuvi), a monoclonal antibody approved in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.Targeted ...
Join